Pushing the positive in p=0.05, RedHill says it’s ready for a pivotal IBD test
RedHill BioPharma $RDHL pushed hard to tout the data from a Phase II study for irritable bowel disease, but the stock started to slide this morning as the online gambling crowd started to tease out the meaning of the p=0.05 bottom line that came with the data.
That’s right on the border of victory and defeat in a clinical study, and not all observers were ready to cheer the data alongside Redhill execs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.